Home  |  About JAPTR |  Editorial board  |  Search |  Ahead of print  |  Current issue  |  Archives |  Submit article  |  Instructions  |  Subscribe  |  Advertise  |  Contacts  |Login 
Users Online: 165   Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
     

    Article Cited by others

ORIGINAL ARTICLE

Anticoagulation control among patients with nonvalvular atrial fibrillation: A single tertiary cardiac center experience

Mohammed Shaban, Aljundi Amer H. S., Kasem Mohamed, Alhashemi Mohammed, El-Menyar Ayman

Year : 2017| Volume: 8| Issue : 1 | Page no: 14-18

   This article has been cited by
 
1 Estratégias Econômicas e Sociais para Anticoagulação de Pacientes com Fibrilação Atrial
Andressa Zulmira Avila Guerrero, Enia Lucia Coutinho, Marcos Bosi Ferraz, Claudio Cirenza, Marcelo Cincotto Esteves dos Santos, José Roberto Ferraro, Angelo Amato Vincenzo de Paola
Arquivos Brasileiros de Cardiologia. 2022; 118(1): 88
[Pubmed]  [Google Scholar] [DOI]
2 Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy
François Laliberté,Veronica Ashton,Akshay Kharat,Dominique Lejeune,Kenneth Todd Moore,Young Jung,Patrick Lefebvre,Jeffrey S Berger
Journal of Comparative Effectiveness Research. 2021;
[Pubmed]  [Google Scholar] [DOI]
3 Anticoagulation Control in Different Ethnic Groups Receiving Vitamin K Antagonist for Stroke Prevention in Atrial Fibrillation
Nur Azyyati Zawawi, Izzati Abdul Halim Zaki, Long Chiau Ming, Hui Poh Goh, Hanis Hanum Zulkifly
Frontiers in Cardiovascular Medicine. 2021; 8
[Pubmed]  [Google Scholar] [DOI]
4 Drive-up INR testing and phone-based consultations service during COVID -19 pandemic in a pharmacist-lead anticoagulation clinic in Qatar: Monitoring, clinical, resource utilization, and patient- oriented outcomes
Eman N. Alhmoud,Osama Badry Abd El Samad,Hazem Elewa,Ola Alkhozondar,Ezeldin Soaly,Rasha El Anany
JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 2021; 4(9): 1117
[Pubmed]  [Google Scholar] [DOI]
5 Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US)
Jeffrey S. Berger,François Laliberté,Akshay Kharat,Dominique Lejeune,Kenneth Todd Moore,Young Jung,Patrick Lefebvre,Veronica Ashton
Advances in Therapy. 2021;
[Pubmed]  [Google Scholar] [DOI]
6 Time to Stable Therapeutic Range on Initiation of Warfarin as an Indicator of Control
Narong Puttasung,Andrew K Davey,Tony Badrick,Shailendra Anoopkumar-Dukie,Nijole Bernaitis
Journal of Stroke and Cerebrovascular Diseases. 2021; 30(4): 105620
[Pubmed]  [Google Scholar] [DOI]
7 Evaluation of the Validity of SAMe-TT2R2 Score in a Cohort of Venous Thromboembolism Patients Treated With Warfarin
Eman Nawash Alhmoud, Hazem Elewa, Mohammed S. Abdul Gelil, Osama B. Abd El Samad, Abdelnasser Y. Elzouki
Clinical and Applied Thrombosis/Hemostasis. 2020; 26: 1076029620
[Pubmed]  [Google Scholar] [DOI]

 

Read this article